We'd appreciate your feedback. Send feedback Subscribe to our newsletters and alerts


Interdisciplinary Research in Medical Sciences Specialty

2021 Volume 1 Issue 1
Creative Commons License

Predictive Value of Macrophage Migration Inhibitory Factor in No-Reflow Phenomenon in STEMI Patients


, , ,
  1. Department of Prevention and Treatment of Emergency Conditions, Government Institution “L.T. Malaya Therapy National Institute NAMSU,” Kharkiv, Ukraine.

     
  2. Department of Internal Medicine, Faculty of Medicine, Zaporozhye State Medical University, Zaporozhye, Ukraine.

Abstract

This study was conducted to determine whether macrophage migration inhibitory factor (MIF) levels predict no-reflow in patients with ST-segment elevation myocardial infarction (STEMI). We included 120 STEMI patients who had received initial PCI therapy. Serial 12-lead ECGs acquired before and after primary PCI within 1-2 hours at 50 mm/sec were used to assess the ST-segment dynamics. When microcirculatory perfusion is compromised, the dynamics of ST-segment elevation resolution (STR) remain at 70% or less. No-reflow was detected using real-time myocardial perfusion imaging by myocardial blush grade assessment. MIF levels were assessed using ELISA before and after PCI. We found that the pre-PCI MIF contents did not significantly differ from the post-PCI MIF levels and that the total population of STEMI patients had higher plasma MIF contents than the group of healthy volunteers (3400 [2089.0-5571.0] pg/mL and 721 [567.3-1104.1] pg/mL, respectively, P < 0.001). MIF levels before and after PCI were significantly higher in patients with no-reflow than in those without it. According to ROC characteristics, the pre-PCI MIF levels that predicted the no-reflow condition had a well-balanced cut-off of 3663 pg/mL (sensitivity = 74%, specificity = 72%, 95% CI = 0.585-0.857; P = 0.0023). The no-reflow was predicted by pre-PCI MIF levels > 3663 pg/mL, whereas post-PCI MIF levels showed no discriminative potency for it. The no-reflow phenomena were independently predicted by female gender and pre-PCI MIF levels > 3663 pg/mL. Higher pre-PCI MIF levels (> 3663 pg/mL and > 5033 pg/mL, respectively) in STEMI patients were predictive of systolic cardiac dysfunction and the post-procedural no-reflow phenomena.


How to cite this article
Vancouver
Storozhenko TY, Vishnevskaya IR, Kopytsya MP, Berezin AE. Predictive Value of Macrophage Migration Inhibitory Factor in No-Reflow Phenomenon in STEMI Patients. Interdiscip Res Med Sci Spec. 2021;1(1):32-45.
APA
Storozhenko, T. Y., Vishnevskaya, I. R., Kopytsya, M. P., & Berezin, A. E. (2021). Predictive Value of Macrophage Migration Inhibitory Factor in No-Reflow Phenomenon in STEMI Patients. Interdisciplinary Research in Medical Sciences Specialty, 1(1), 32-45.

About GalaxyPub

Find out more

Our esteemed publisher is committed to advancing medical knowledge through rigorous research dissemination. We exclusively accept submissions related to the field of medicine.

Our journals provide a platform for clinicians, researchers, and scholars to share groundbreaking discoveries, clinical insights, and evidence-based practices. By maintaining this specialized focus, we ensure that their publications contribute significantly to the advancement of healthcare worldwide.